Phillip Pang - Jan 2, 2024 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)

Role
EVP & Chief Medical Officer
Signature
/s/ Sung Lee, Attorney-in-Fact
Stock symbol
VIR
Transactions as of
Jan 2, 2024
Transactions value $
$0
Form type
4
Date filed
1/3/2024, 02:47 PM
Previous filing
Jun 8, 2023
Next filing
Feb 16, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VIR Common Stock Options Exercise $16.1K +18.8K +10.02% $0.86 207K Jan 2, 2024 Direct
transaction VIR Common Stock Options Exercise $21.4K +13.6K +6.56% $1.58 220K Jan 2, 2024 Direct
transaction VIR Common Stock Options Exercise $72.8K +47.6K +21.59% $1.53 268K Jan 2, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VIR Stock Option (Right to Buy) Options Exercise -$16.1K -18.8K -100% $0.86 0 Jan 2, 2024 Common Stock 18.8K $0.86 Direct F1
transaction VIR Stock Option (Right to Buy) Options Exercise -$21.4K -13.6K -100% $1.58 0 Jan 2, 2024 Common Stock 13.6K $1.58 Direct F2
transaction VIR Stock Option (Right to Buy) Options Exercise -$72.8K -47.6K -100% $1.53 0 Jan 2, 2024 Common Stock 47.6K $1.53 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/4 of the shares subject to the stock option vested and became exercisable on December 14, 2017, and the remaining shares vested in 36 equal monthly installments thereafter.
F2 1/4 of the shares subject to the stock option vested and became exercisable on July 19, 2019, and the remaining shares vested in 36 equal monthly installments thereafter.
F3 1/4 of the shares subject to the stock option vested and became exercisable on April 27, 2019, and the remaining shares vested in 36 equal monthly installments thereafter.